We first provided a listing (with very few details) of industry-sponsored late-stage (pivotal, phase 3 and 2/3) cell therapy clinical trials on this blog late last year (see the posting here).
We are now pleased to we have worked with Genetic Engineering and Biotechnology News and Enal Razvi of Select Biosciences to provide an updated (as of June 2012) and more detailed listing of industry-sponsored late-stage (pivotal, phase 3 and 2/3) cell therapy clinical trials (excluding cell-based immunotherapies which we intend to cover in a follow-up article).
A link to the listing can be found in an article published today entitled "Cellular Therapy Wave Finally Cresting" found in the November 1, 2012 issue of GEN.
While not my favorite title, the article is a brief - but we hope useful - overview of the sector and its pipeline. It also provides a snapshot of the cell therapy products already in commercial distribution.
Some will quibble about the numbers. Certainly others have published larger revenue numbers, for instance, but in our view these have almost always included revenue from cord blood banking which we have excluded.
We encourage you to read the article but for convenience here is a direct link to the spreadsheet. Of course it's already out-dated but we'll do an update again soon here on this blog.
Hope this is useful.
--Lee
Recommendation and review posted by Fredricko
